Inclusion Criteria  Histologically/cytologically confirmed diagnosis of locally advanced or metastatic (Stage IIb to IV) NSCLC with EGFR ex20ins mutations (based on the evaluation by the treating center) between 01 January 2017 and 30 September 2021. Followed-up at the site between 01 January 2017 and 30 September 2021 for his/her advanced NSCLC, irrespective of their current survival status.  Exclusion Criteria  1. Participants whose investigator has access to fewer than two registered visits for his/her advanced NSCLC between 01 January 2017 and 30 September 2021.